THERAPY DOSSIER · th-a1ef79127857

Sitagliptin

Drug · CHEMBL1422, max_phase 4, first approval 2006, ATC A10BH01, USAN stem -gliptin. Mechanisms mec_id 466, 9654 and 10022 are all concordant: dipeptidyl peptidase IV (DPP-4) INHIBITOR, target CHEMBL284, direct_interaction true, disease_efficacy true. Salt form CHEMBL1201174 (sitagliptin phosphate) maps to the same parent. EXACT entity match.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: CHEMBL1422, max_phase 4, first approval 2006, ATC A10BH01, USAN stem -gliptin. Mechanisms mec_id 466, 9654 and 10022 are all concordant: dipeptidyl peptidase IV (DPP-4) INHIBITOR, target CHEMBL284, direct_interaction true, disease_efficacy true. Salt form CHEMBL1201174 (sitagliptin phosphate) maps to the same parent. EXACT entity match.
Target: CHEMBL284
Injury models: Other
Reported indication: Type 2 diabetes mellitus (DPP-4 inhibitor; Januvia, approved 2006)
First approval: 2006
Development stage: Approved for T2DM; diabetic-foot/wound-healing use investigational
ChEMBL record: CHEMBL1422 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Januvia; Janumet; MK-0431; Xelevia; Tesavel; Ristaben; Zituvio; Sitagliptin phosphate
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02675335 ↗PHASE3withdrawn

Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin

Diabetic Foot

Enrolment: 0 · Results not recorded

NCT02406950 ↗PHASE3unknown

Preventive Effects of Sitagliptin on Endothelial Dysfunction Induced by Forearm Ischemia-Reperfusion Injury

Healthy

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25499391 ↗2014Reported benefit

Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells.

MouseOtherC57Bl/6MaleShort-term treatment after acute carotid endothelial injury

Model: Defined acute endothelial injury of the carotid artery

Sitagliptin prevented SDF-1alpha degradation, increased recruitment of CXCR4 positive progenitor cells and accelerated reendothelialisation without promoting neointimal or medial hyperplasia, with the effect reversed by AMD3100.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…

Sitagliptin